Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, headquartered in Great Britain, is a leading biopharmaceutical company dedicated to developing innovative treatments for patients with serious conditions. Founded in 2003, Jazz has made significant strides in the industry, particularly in the areas of sleep medicine and neurology.
The company’s core products, including Xyrem and Sunosi, are renowned for their unique formulations that address complex health issues such as narcolepsy and excessive daytime sleepiness. With a strong market position, Jazz Pharmaceuticals has achieved notable milestones, including strategic acquisitions that have expanded its therapeutic portfolio and global reach.
Operating primarily in North America and Europe, Jazz Pharmaceuticals continues to focus on delivering high-quality, patient-centric solutions that enhance the quality of life for individuals facing challenging health conditions.
-17 vs industry average
Jazz Pharmaceuticals’s score of 21 is lower than 42% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Jazz Pharmaceuticals?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Jazz Pharmaceuticals yet.
Jazz Pharmaceuticals's reported carbon emissions
Jazz Pharmaceuticals, headquartered in Great Britain, currently does not have available data on its carbon emissions, as indicated by the absence of specific emissions figures. The company has not outlined any documented reduction targets or commitments to climate initiatives, which suggests a lack of formalised strategies in this area.
As of now, there are no emissions data cascaded from a parent or related organisation, indicating that Jazz Pharmaceuticals operates independently regarding its climate impact reporting. Without specific emissions data or reduction initiatives, it is unclear how the company is addressing its carbon footprint or contributing to broader climate goals within the pharmaceutical industry.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Jazz Pharmaceuticals’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Jazz Pharmaceuticals yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Jazz Pharmaceuticals
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project